文献速递基础与转化研究临床试验与 GCP

CD19与CD22双靶向CAR-T治疗成人复发或难治性B细胞恶性肿瘤的I期试验

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
PubMed 文献 · Nat Med · 2021-07-26

该I期试验在复发或难治性B细胞急性淋巴细胞白血病(B-ALL)和大B细胞淋巴瘤(LBCL)成人患者中测试CD19-22双特异性CAR-T。主要终点制造可行性和安全性均达到,B-ALL患者100%缓解、88%微小残留病阴性完全缓解,LBCL患者62%缓解、29%完全缓解;复发多为CD19阴性或低表达,未与CD22阴性或低表达相关。

要点

  • CD19-22双靶向CAR-T在B-ALL中100%缓解、88%微小残留病阴性完全缓解
  • LBCL中62%缓解、29%完全缓解,复发多为CD19阴性或低表达
  • CD22刺激下CAR-T细胞因子产生减少,提示双靶点效力不等

核心结论

  • CD19-22双靶向CAR-T制造可行且安全,在B-ALL和LBCL中显示疗效。
  • 抗原丢失是CAR-T耐药的主要原因,双特异性CAR-T需实现靶点间等效效力。

研究设计与样本

  • I期临床试验(NCT03233854),纳入成人复发或难治性B-ALL和LBCL患者。
  • 主要终点为制造可行性和安全性,次要终点为疗效。

主要发现

  • 97%产品达到方案规定剂量,剂量递增期间未发生剂量限制性毒性。
  • B-ALL(n=17)100%缓解,88%达微小残留病阴性完全缓解。
  • LBCL(n=21)62%缓解,29%完全缓解。
  • B-ALL复发者中50%(5/10)为CD19阴性或低表达,LBCL复发者中29%(4/14)为CD19阴性或低表达,均未与CD22阴性或低表达相关。
  • CD22刺激较CD19刺激下CD19/22-CAR产品细胞因子产生减少。

关键数值与推荐

  • CAR19治疗后进展的16例LBCL患者中10例CD19缺失或低表达。
  • 治疗前CD19表面密度较低与疾病进展相关。

临床怎么用

  • 双靶向CAR-T可用于CD19阳性或低表达B细胞恶性肿瘤,但需关注CD19阴性复发。
  • 细胞因子产生可作为CAR-T效力的质量指标。

局限性

  • I期试验样本量小,疗效需更大规模验证。
  • 双特异性CAR-T在不同靶点间效力不等,CD22刺激下细胞因子产生减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated with progressive disease. To prevent relapse with CD19- or CD19lo disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial ( NCT03233854 ) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. The primary end points were manufacturing feasibility and safety with a secondary efficacy end point. Primary end points were met; 97% of products met protocol-specified dose and no dose-limiting toxicities occurred during dose escalation. In B-ALL (n = 17), 100% of patients responded with 88% minimal residual disease-negative complete remission (CR); in LBCL (n = 21), 62% of patients responded with 29% CR. Relapses were CD19-/lo in 50% (5 out of 10) of patients with B-ALL and 29% (4 out of 14) of patients with LBCL but were not associated with CD22-/lo disease. CD19/22-CAR products demonstrated reduced cytokine production when stimulated with CD22 versus CD19. Our results further implicate antigen loss as a major cause of CAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Spiegel JY, Patel S, Muffly L, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021. PMID: 34312556. doi:10.1038/s41591-021-01436-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。